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Background. Metalloproteinases (MMPs) play a pivotal role during the process of trophoblast invasion and placentation. The
appearance of five functional single-nucleotide polymorphisms (SNP) in the genes of the metalloproteinases most commonly
implicated in the implantation process may influence the development of preeclampsia. Methods. Blood samples were collected
from 86 mothers and 86 children after preeclampsia and 85 mothers and 85 children with uncomplicated pregnancies. The
distribution of genotypes for −1607 1G/2G MMP1, −735 C/T MMP2, −1306 C/T MMP2, −1171 5A/6A MMP3, and −1562C/T
MMP9 polymorphisms was determined by RFLP-PCR. Results. The occurrence of 1G/1G MMP1 or 5A/5A MMP3 genotype in
the mother or 1G/1G MMP1 or 5A/6A MMP3 genotype in the child is associated with preeclampsia development. Moreover,
simultaneous maternal and fetal 1G/1G homozygosity increases the risk of preeclampsia development 2.39-fold and the set of
maternal 5A/5A and fetal 5A/6A MMP3 genotypes by over 4.5 times. No association between the carriage of studied MMP2 or
MMP9 polymorphisms and the predisposition to preeclampsia was found. Conclusion. The maternal 1G/1G MMP1 and 5A/5A
MMP3 and fetal 1G/1G MMP1 and 5A/6A MMP3 gene polymorphisms may be strong genetic markers of preeclampsia,
occurring either individually or together.
1. Introduction
Primary preeclampsia is a multifactorial disease. According
to the American College of Obstetricians and Gynecologists
(ACOG) criteria, preeclampsia is defined as gestational
hypertension typified by ≥140mmHg systolic or ≥90mm
Hg diastolic blood pressure measured on at least two occa-
sions, accompanied by proteinuria, manifested as ≥0.3 g in
a 24-hour collection of urine or ≥1+ in occasional urine
samples, noticed after 20 weeks of gestation [1, 2]. The
International Society for the Study of Hypertension in
Pregnancy (ISSHP) raised the proteinuria threshold to 2+
on a dipstick [1, 3]. However, in the absence of proteinuria,
the new onset of hypertension combined with the maternal
organ dysfunction (according to ACOG and ISSHP criteria)
or uteroplacental dysfunction (according to ISSHP criteria)
is sufficient to recognize preeclampsia [1–3]. Preeclampsia
appears in 5 to 8% of pregnancies and it is also a leading
cause of perinatal morbidity and mortality [4, 5].
Although the precise etiology of preeclampsia is
unknown, it has been suggested that while both genetic and
environmental factors influence its development, genetic
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factors have a greater influence, accounting for over half of
preeclampsia liability cases [6, 7]. Studies indicate that
daughters born after preeclamptic pregnancy may carry
susceptibility genes inherited from their mother, which
predispose them to preeclampsia development [8]. Paternal
genes carried by the fetus are also responsible for triggering
preeclampsia development, but this risk is lower than the risk
associated with the carriage of maternal genes [8, 9].
One of the most probable pathomechanisms of PE
development is connected with inadequate maternal blood
flow in the placenta, caused by deficient spiral artery remod-
eling and shallow trophoblast invasion. The process of
placentation and the development of embryonic tissue and
the extraembryonic trophoblast depends on the genome,
which consists of both paternal and maternal genes [6].
In physiological conditions, the invasion of the extravil-
lous trophoblast involves the integrin heterodimers which
recognize the laminin/collagen IV and fibronectin in the
decidual extracellular matrix (ECM) [5]. The basement
membrane proteins of a newly synthesized ECM play a
significant role in the crosstalk between fetal and maternal
surfaces. The process of trophoblast adhesion is followed
by enzymatic degradation of the decidual extracellular
matrix, which is mediated principally by matrix metallo-
proteinases (MMPs). Metalloproteinases belong to a large
family of zinc-dependent endopeptidases that include col-
lagenases (e.g., MMP1, MMP8, and MMP13), gelatinases
(MMP2, MMP9), stromelysins (MMP3, MMP10), matrily-
sins (MMP7, MMP26), and transmembrane metalloprotein-
ases types I and II. All are collectively capable of degrading
extracellular matrix components, but numerous studies have
particularly implicated MMP1, MMP2, MMP3, and MMP9
in the process of trophoblast implantation. The invading
trophoblast cells are not alone in the process of metallopro-
teinase secretions: MMPs are also expressed by endometrial
stromal cells, natural killer (NK) cells, and macrophages of
the decidual area [10]. Immunohistochemical and biochemi-
cal studies performed on placentas and deciduas indicate an
imbalance in the metalloproteinase secretions both by tro-
phoblast and decidual cells in pregnancies complicated by
preeclampsia [5, 11, 12].
Although the level of metalloproteinase gene expression
is regulated by transcriptional and posttranscriptional
mechanisms, the first one exerts the most influence. Most
MMPs share common sequences in their promoter regions
which create the binding sites for the following transcrip-
tion factors: the activator protein- (AP-) 1 and -2 sites,
the polyomavirus enhancer-A binding protein-3 (PEA3)
site, the SP-1 site, the NF-κB site, and the STAT site
[13, 14]. Changes in the nucleotide sequences in the binding
sites of transcription factors or transcription repressors alter
the regulation of MMP gene expression and thus may have
an impact on the improper placentation of the trophoblast
into the uterine wall.
The aim of the present study was to determine whether
the most common MMP1, MMP2, MMP3, and MMP9
gene polymorphisms in maternal and fetal genes are asso-
ciated with preeclampsia. All selected polymorphisms:
−1607 1G/2G MMP1 (rs1799750), −735 C/T MMP2
(rs2285053), −1306 C/T MMP2 (rs243865), −1171 5A/6A
MMP3 (rs35068180) and −1562C/T MMP9 (rs3918242) are
functional, are localized in the promoter region of MMPs,
are responsible for the regulation of MMP gene expression,
and thus may affect the amount of protein synthesized. It also
examines whether the set of maternal/fetal genotypes and
whether the sex of the fetus and its genotype with regard to
the studied polymorphisms influence the predisposition to
preeclampsia development.
2. Material and Methods
2.1. Study and Control Groups. This is a case-control study
including preeclamptic (N = 86) women and their children
(N = 86) and those who are healthy with uncomplicated
pregnancies (N = 85 mothers and N = 85 children). All
members of the study group were Caucasians and residents
in Poland. The study group included women, and their chil-
dren, who developed maternal blood pressure higher than
140/90mm·Hg (measured twice with an interval of at least
six hours) with accompanied proteinuria (>300mg per 24
hours or at least 2+ during a single urine test) after the 20th
week of gestation. The study group included both patients
with early (<34 weeks of pregnancy; N = 31) preeclampsia
and late (≥34 weeks of pregnancy; N = 55) preeclampsia.
The remaining qualification criteria for examination
were the same for the control and study groups: single
pregnancy, no hypertension or diabetes mellitus before
pregnancy, no gestational diabetes mellitus, no chromosomal
aberration in the fetus, maternal body mass index (BMI)
before pregnancy≤ 30 kg/m2, and no other chronic maternal
disorders. Informed consent was signed by each mother
before delivery, and the study protocol was approved
by the Medical University of Lodz Ethical Committee
(number RNN/212/11/KE).
Whole venous blood was taken from all participants one
to two hours before the beginning of delivery, whereas the
umbilical blood was obtained immediately after birth. As all
women in the preeclamptic group delivered the baby by
caesarian section, due to clinical indications, the control
samples were also collected from women who had delivered
their baby by caesarian section. Indications for caesarian
delivery in the control group were as follows: transverse or
breech position of fetus, ophthalmological indications, ortho-
pedic indications, or increased risk of uterine rupture because
of previously performed cesarean delivery.
2.2. Method of Genotyping. DNA was isolated from maternal
and fetal blood with the use of a commercial kit (Chemagen,
Germany). The primers for PCR reaction were as follows:
MMP1_F_5′-GAG TAT ATC TGC CAC TCC TTG AC-3′,
MMP1_R_5′-CTT GGA TTG ATT TGA GAT AAG TCA
TAg C-3′, MMP2_-735C/T_F_5′-GGT GGG TGC TTC
CTT TAA CAT G-3′, MMP2_-735C/T_R_5′-GTA AAA
TGA GGC TGA GAC CTG C-3′, MMP2_-1306C/T_F_5′-
CTT CCT AGG CTG GTC CTT ACT G-3′, MMP2_
-1306C/T_R_5′-GCT GAG ACC TGA AGA GCC A-3′,
MMP3_F_5′-CAT TCC TTT GAT GGG GGG AAA gA-3′,
MMP3_R_5′-GAA GGA ATT AGA GCT GCC ACA
2 Disease Markers
GC-3′, MMP9_F_5′-GCA GAT CAC TTG AGT CAG
AAG TTC-3′, MMP9_R_5′-GGG AAA AAC CTG CTA
ACAACTC-3′. The following restriction endonucleases were
used: AluI, HinfI, BstXI, Tth111I, and SphI (Thermo Fisher
Scientific, USA). The products of digestion were analyzed on
6% polyacrylamide gel and dyed with ethidium bromide.
2.3. Statistical Analyses. Data analysis was performed using
Statistica v12 (StatSoft, Tulsa, OK). The clinical and per-
sonal characteristics data was normally distributed and so
was compared between groups using Student’s t-test. The
Hardy–Weinberg equilibrium was tested in maternal and
fetal control groups. Nominal variable comparisons were
performed using chi2 or Yates’ corrected chi2 tests. Multivar-
iate analysis was performed with backward stepwise logistic
regression on variables found to be significant (p < 0 05) in
univariate analyses. Odds ratios (OR) with 95% confidence
intervals (95% CI) were calculated for significant parameters
obtained by multivariate and univariate analyses.
Haplotype analysis (haplotype frequency estimation and
linkage disequilibrium) was performed between the maternal
study and control groups and between the group of fetuses
born from preeclamptic and those born from noncompli-
cated pregnancies; online SNPStat software was used for this
purpose (https://www.snpstats.net/snpstats/) [15]. For each
haplotype onset, the cumulative frequency was calculated;
in addition, the association between the most frequent
haplotype onsets (regarded as a cumulative frequency for
haplotype onset score below 0.9) and preeclampsia was also
calculated by logistic regression in SNPStat software. The
results of the logistic regression were presented as ORs and
95% CI and p values.
Moreover, the Generalized Multifactor Dimensionality
Reduction (GMDR, v0.9; http://www.ssg.uab.edu/gmdr/)
[16, 17] analysis was used to calculate the interaction
among five studied polymorphisms (−1607 1G/2G MMP1
(rs1799750), −735 C/T MMP2 (rs2285053), −1306 C/T
MMP2 (rs243865), −1171 5A/6A MMP3 (rs35068180), and
−1562C/T MMP9 (rs3918242)) in predicting of the occur-
rence of preeclampsia. Maximum testing balanced accuracy
(TBA) and cross-validation consistency (CVC) were used to
select the best interaction model, and the results of analyses
were considered to be statistically significant at p < 0 05.






(N = 85) p value
Age of women (years)1 30.7± 6.2 32.0± 4.3 0.129
BMI (kg/m2)1 26± 3.1 25± 4.3 <0.05
WBC (103/μl)1 10.6± 2.3 10.7± 2.3 0.712
RBC (106/μl)1 4.1± 0.5 4.1± 0.4 0.648
HB (g/dl)1 12.2± 1.4 12.4± 1.1 0.474
HCT (%)1 35.7± 3.4 36.2± 2.5 0.313
MCV (fl)1 85.4± 6.5 87.1± 5.2 0.071
MCHC (g/dl)1 34.3± 2.6 33.8± 1.7 0.126
PLT (103/μl)1 203.4± 60.5 220.4± 54.2 0.057
History of miscarriage n (%)2 16 (19%) 13 (15%) 0.564
Week of delivery for early PE1 (N = 31) 31.6± 2.0 38.5± 1.0 <0.0001






(N = 85) p value
Baby weight (g)1 2469± 923 3407± 448 <0.001
Baby height (cm)1 49.0± 6.4 54.1± 2.8 <0.001
Apgar score—1 minute1 8.6± 1.4 9.4± 0.8 <0.001
Baby sex (son), N (%)2 52 (60%) 38 (45%) <0.05
1The values are presented as mean ± standard deviation. For data analysis, Student’s t-test was used. 2For data analysis, the chi-squared test was used; BMI: body
mass index; WBC: white blood cells; RBC: red blood cells; HB: haemoglobin concentration; HCT: haematocrit; MCV: mean corpuscular volume; MCHC: mean
corpuscular haemoglobin concentration; PLT: platelets; kg/m2: kilograms/meter square; μl: microlitre; g/dl: grams/decilitre; %: percent; fl: femtolitre; g: grams;
cm: centimetre; N: number of cases.
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3. Results
3.1. Baseline of the Study and Control Population. A total of
171 cases: 86 mothers and 86 children after preeclampsia
and 85 mothers and 85 children with uncomplicated preg-
nancies were enrolled to this study. The comparisons of the
baseline laboratory parameters and the characteristics of the
patients of the study and control groups are summarized
in Table 1.
3.2. The Influence of Maternal and Fetal MMP Gene
Polymorphisms on the Risk of Preeclampsia Development. A
week of linkage disequilibrium between studied polymor-
phisms was observed (Table 2).
Univariate analyses of the studied polymorphisms of
maternal and fetal genotypes revealed that the maternal
homozygosity of MMP1 1G/1G and the maternal homozy-
gosity of MMP3 5A/5A are more common among pre-
eclamptic women. No associations between the occurrence
of preeclampsia and the distribution of genotypes or alleles
of studied maternalMMP2 andMMP9 gene polymorphisms
were observed. The distribution of genotypes and alleles
in the maternal study and control groups are presented
in Table 3.
Univariate analyses related to distribution of genotypes
and alleles of studied −1607 1G/2G MMP1 (rs1799750),
−735 C/TMMP2 (rs2285053), −1306 C/T MMP2 (rs243865),
−1171 5A/6A MMP3 (rs35068180), and −1562C/T MMP9
(rs3918242) gene polymorphisms among preeclamptic
and control children found that the homozygosity of
MMP1 1G/1G dominates in the group of children born
from preeclamptic pregnancies. Additionally, the univariate
analyses revealed that fetal heterozygosity 5A/6A MMP3 is
significantly more frequent in the population of preeclamp-
tic children. No associations between occurrence of pre-
eclampsia and the distribution of genotypes or alleles of
studied fetal MMP2 and MMP9 gene polymorphisms were
observed. The distribution of genotypes and alleles in the
fetal study and control groups is presented in Table 4.
The distribution of all studied genotypes in the maternal
and fetal control groups was consistent with the Hardy–
Weinberg equilibrium.
Significant clinical parameters and statistically relevant
maternal and fetal genotypes were included in the multi-
variable analysis. The results of this analysis are presented
in Table 5.
Because fetal sex differed significantly among preeclamp-
tic and noncomplicated pregnancies, it was interesting
whether there exists some relationships in distribution of
MMP genotypes in respect to fetal sex among study and
control groups. This analysis reveals that the 1G/1G genotype
ofMMP1 gene was significantly higher in the group of female
preeclamptic children whereas 2G/2G genotype of MMP1
dominated in the group of female and male children born
from noncomplicated pregnancies. Moreover, this analysis
pointed out that the carriage of 5A/6A genotype by male
children is associated to preeclampsia occurrence whereas
male fetal homozygous 6A/6A of MMP3 dominate in non-
complicated pregnancies (Table 6).
Test of haplotypes identified a lot of their sets; how-
ever, any differences in the frequency haplotypes between
the study and control groups of women were observed
(Table 7). The results of the frequency of haplotypes among
children born from preeclamptic and noncomplicated preg-
nancies have shown that only one haplotype 1G-5A-C-C-T
is associated with the elevated maternal risk of occurrence
of preeclampsia (OR=5.93, 95% CI 1.06–33.19; p = 0 044).
No other differences for frequency of haplotypes in children
group were observed (Table 7).
According to the GMDR selection model, the best
model among the maternal group was a two-SNP interac-
tion model, containing −1607 1G/2G MMP1 (rs1799750)
and −1171 5A/6A MMP3 (rs35068180), with the maximum
cross-validation consistency (CVC) of 10/10 and with the
maximum testing balanced accuracy (TBA)= 64.25% and
significance of the test p = 0 0107. The second was a three-
SNP interaction model, containing −1607 1G/2G MMP1
(rs1799750), −1171 5A/6A MMP3 (rs35068180), and
−1562C/T MMP9 (rs3918242), with the maximum CVC
(9/10), TBA=61.97%, and p = 0 0107.
The GMDR analysis used to calculate the interaction
among 5 studied polymorphisms in predicting preeclampsia
based on the gene-gene interaction in the children group has
shown that the best model is containing only −1607 1G/2G
MMP1 (rs1799750) nucleotide polymorphisms, with the
CVC (10/10), TBA=63.82%, and p = 0 0107. The second
model was based on a two-SNP interaction model containing
−1607 1G/2G MMP1 (rs1799750) and −1171 5A/6A MMP3
(rs35068180), with the maximum cross-validation consis-
tency (CVC) of 4/10 and with the maximum testing balanced
accuracy (TBA)=57.91% and significance of the test p =
0 0107. The last model based on a three-SNP interac-
tion model containing −1607 1G/2G MMP1 (rs1799750),
−1171 5A/6A MMP3 (rs35068180), and −1562C/T MMP9
(rs3918242), with the CVC (7/10) and TBA=53.92% was
not statistically significant having p = 0 1719.
Because in all statistical tests we observed the contribu-
tion of 1G/2G MMP1 and 5A/6A MMP3 polymorphisms in
Table 2: Linkage disequilibrium between studied polymorphisms.
MMP3 rs35068180 (D’) MMP9 rs3918242 (D’) MMP2 rs2285053 (D’) MMP2 rs243865 (D’)
MMP1 rs1799750 (D’) 0.22 0.17 0.03 0.03
MMP3 rs35068180 (D’) 0.30 0.27 0.07
MMP9 rs3918242 (D’) 0.31 0.07
MMP2 rs2285053 (D’) 0.25
D’is equal to D scaled in [−1,1] range where D is the deviation between the expected haplotype frequency and the observed frequency.
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the development of preeclampsia, we conduct the additional
analyses focusing on simultaneous carriage of maternal
(MMP1 and MMP3) or fetal (MMP1 and MMP3) or both
maternal and fetal MMP1 and MMP3 gene polymorphisms
and the predisposition to preeclampsia. These analyses
revealed that simultaneously maternal homozygosity in
1G/1G MMP1 and 5A/5A MMP3 increases the risk of pre-
eclampsia development over 10-fold (OR=10.22, 95% CI
2.28–45.8; p < 0 01). We also observed that the fetal genotype
elevates the maternal risk of preeclampsia development
(OR=6.54, 95% CI 2.13–20.01; p < 0 01) for simultaneous
carriers of 1G/1GMMP1 and 5A/6AMMP3 polymorphisms.
Additionally, we observed that simultaneous maternal and
fetal 1G/1G homozygosity increases the risk of preeclamp-
sia development 2.39-fold (OR=2.39, 95% CI 1.01–5.65),
whereas the set of maternal 5A/5A and fetal 5A/6A MMP3
genotypes elevates the risk of occurrence of the studied
disease 4.57 times (OR=4.57, 95% CI 1.85–11.26).
4. Discussion
The regulation of metalloproteinase (MMP) secretion in the
maternal-fetal interface plays a pivotal role in the process of
trophoblast invasion and placentation. MMPs are known to
be secreted by trophoblastic cells, and studies suggest that
they are also expressed by maternal endometrial stromal cells
and immunological cells which migrate into the uterus
during perimenstrual and early pregnancy phases [10, 18].
Disturbances in metalloproteinase secretion by trophoblast
or maternal cells may impair the process of trophoblastic
invasion and placentation, thus inducing pregnancy-related
disease such as preeclampsia or IUGR development.
Table 3: Comparison of maternal genotypes between the preeclamptic and study groups.








−1607 1G/2G MMP1 (rs1799750)
1G/1G 30 (35%) 14 (16%) <0.01
0.7121G/2G 22 (25%) 43 (51%) <0.01
2G/2G 34 (40%) 28 (33%) 0.369
1G 82 (48%) 71 (42%)
0.272
2G 90 (52%) 99 (58%)
−1171 5A/6A MMP3 (rs35068180)
5A/5A 32 (37%) 12 (14%) <0.01
0.5855A/6A 31 (36%) 43 (51%) 0.055
6A/6A 23 (27%) 30 (35%) 0.226
5A 95 (55%) 67 (39%) <0.01
6A 77 (45%) 103 (61%)
−1562C/T MMP9 (rs3918242)
CC 61 (71%) 57 (67%) 0.584
0.629CT 25 (29%) 26 (31%) 0.828
TT 0 (0%) 2 (2%) 0.472
C 147 (85%) 140 (82%)
0.433
T 25 (15%) 30 (18%)
−735 C/T MMP2 (rs2285053)
CC 67 (78%) 66 (78%) 0.967
0.481CT 19 (22%) 17 (20%) 0.737
TT 0 (0%) 2 (2%) 0.472
C 153 (89%) 149 (88%)
0.707
T 19 (11%) 21 (12%)
−1306 C/T MMP2 (rs243865)
CC 52 (60%) 49 (58%) 0.708
0.636CT 30 (35%) 30 (35%) 0.955
TT 4 (5%) 6 (7%) 0.730
C 134 (78%) 128 (75%)
0.568
T 38 (22%) 42 (25%)
aFor p value analysis, the chi2 or Yates’ corrected chi2 tests were used; bHWE: Hardy–Weinberg equilibrium.
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The present study examines whether the occurrence
of single-nucleotide polymorphisms (SNP) in the MMP1,
MMP2, MMP3, and MMP9 genes is related to the out-
come of preeclampsia. Our results show that the maternal
1G/1G MMP1 and 5A/5A MMP3 gene polymorphisms
occur significantly more frequently in preeclamptic cases.
No relationship was observed between the maternal or fetal
polymorphisms of MMP2 and MMP9 genes and adverse
pregnancy outcome. The −1562C/T MMP9, −735 C/T, and
−1306 C/T MMP2 polymorphisms were localized in the
promoter region of metalloproteinase genes, and numerous
studies have implicated them in the regulation of gene
expression. As the cytosine form of the −1562C/T MMP9
polymorphism creates a binding site for a transcription
repressor protein, the thymidine variant should induce
higher relative MMP9 gene expression: this has been con-
firmed on MALU cells [19]. Immunohistochemical experi-
ments comparing preeclamptic women with age-matched
controls based on placental sections of decidual cells and
adjacent interstitial trophoblasts revealed that an elevated
level of MMP9 is characteristic for gestation complicated
Table 4: Comparison of genotypes between children born from preeclamptic and noncomplicated pregnancies.








−1607 1G/2G MMP1 (rs1799750)
1G/1G 30 (35%) 12 (14%) <0.01
0.5031G/2G 43 (50%) 36 (42%) 0.316
2G/2G 13 (15%) 37 (44%) <0.001
1G 103 (60%) 60 (35%) <0.0001
2G 69 (40%) 110 (65%)
−1171 5A/6A MMP3 (rs35068180)
5A/5A 12 (14%) 17 (20%) 0.291
0.8415A/6A 62 (72%) 41 (48%) <0.01
6A/6A 12 (14%) 27 (32%) <0.01
5A 86 (50%) 75 (44%)
0.276
6A 86 (50%) 95 (56%)
−1562C/T MMP9 (rs3918242)
CC 67 (78%) 61 (72%) 0.354
0.487CT 19 (22%) 21 (25%) 0.687
TT 0 (0%) 3 (3%) 0.240
C 153 (89%) 143 (84%)
0.190
T 19 (11%) 27 (16%)
−735 C/T MMP2 (rs2285053)
CC 66 (77%) 69 (81%) 0.477
0.857CT 18 (21%) 15 (18%) 0.586
TT 2 (2%) 1 (1%) 0.992
C 150 (87%) 153 (90%)
0.417
T 22 (13%) 17 (10%)
−1306 C/T MMP2 (rs243865)
CC 50 (58%) 48 (56%) 0.825
0.304CT 27 (31%) 34 (40%) 0.240
TT 9 (11%) 3 (4%) 0.140
C 127 (74%) 130 (76%)
0.573
T 45 (26%) 40 (24%)
aFor p value analysis, the chi2 or Yates’ corrected chi2 tests were used; bHWE: Hardy–Weinberg equilibrium.
Table 5: Multivariable analysis of clinical and genetic factors and
predisposition to preeclampsia.
Parameters OR 95% CI p
BMI 1.13 1.02 1.23 <0.05
Maternal 1G/2G MMP1 genotype 0.33 0.15 0.69 <0.01
Maternal 5A/5A MMP3 genotype 2.76 1.17 6.49 <0.05
Fetal 5A/6A MMP3 genotype 2.44 1.16 5.13 <0.05
Fetal 2G/2G MMP1 genotype 0.31 0.14 0.70 <0.01
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pa OR (95% CI)
−1607 1G/2G MMP1 (rs1799750)
1G/1G 12 (35%) 5 (10%) <0.05 4.58 (1.43–14.67) 18 (35%) 7 (18%) 0.085 NSb
1G/2G 15 (44%) 21 (45%) 0.959 NSb 28 (54%) 15 (39%) 0.176 NSb
2G/2G 7 (21%) 21 (45%) <0.05 0.32 (0.12–0.88) 6 (12%) 16 (42%) <0.01 0.18 (0.06–0.52)
−1171 5A/6A MMP3 (rs35068180)
5A/5A 4 (12%) 9 (19%) 0.557 NSb 8 (15%) 8 (21%) 0.678 NSb
5A/6A 25 (73%) 26 (55%) 0.091 NSb 37 (71%) 15 (39%) <0.01 3.78 (1.56–9.16)
6A/6A 5 (15%) 12 (26%) 0.366 NSb 7 (13%) 15 (39%) <0.01 0.24 (0.08–0.67)
−1562C/T MMP9 (rs3918242)
CC 29 (85%) 32 (68%) 0.131 NSb 38 (73%) 29 (76%) 0.918 NSb
CT 5 (15%) 14 (30%) 0.188 NSb 14 (37%) 7 (18%) 0.490 NSb
TT 0 (0%) 1 (2%) 0.870 NSb 0 (0%) 2 (5%) 0.343 NSb
−735 C/T MMP2 (rs2285053)
CC 25 (73%) 35 (74%) 0.872 NSb 41 (79%) 34 (89%) 0.294 NSb
CT 8 (24%) 11 (23%) 0.801 NSb 10 (19%) 4 (11%) 0.406 NSb
TT 1 (3%) 1 (2%) 0.622 NSb 1 (2%) 0 (0%) 0.874 NSb
−1306 C/T MMP2 (rs243865)
CC 25 (73%) 28 (60%) 0.189 NSb 25 (48%) 20 (53%) 0.669 NSb
CT 8 (24%) 19 (40%) 0.107 NSb 19 (37%) 15 (39%) 0.777 NSb
TT 1 (3%) 0 (0%) 0.870 NSb 8 (15%) 3 (8%) 0.436 NSb
aFor p value analysis, the chi2 or Yates’ corrected chi2 tests were used; bNS: not significant.
Table 7: Haplotype association with the predisposition to preeclampsia.
Haplotype association with preeclampsia occurrence
MMP1 rs1799750 MMP3 rs35068180 MMP9 rs3918242 MMP2 rs2285053 MMP2 rs243865 OR (95% Cl) p value
Maternal haplotype set
(1) 2G 6A C C C 1 —
(2) 1G 5A C C C 0.78 (0.29–2.12) 0.63
(3) 2G 5A C C C 2.90 (0.92–9.17) 0.072
(4) 1G 6A C C C 2.64 (0.77–9.02) 0.12
(5) 2G 6A C C T 0.63 (0.18–2.21) 0.47
(6) 2G 6A C C C 1.66 (0.47–5.83) 0.43
Fetal haplotype set
(1) 2G 6A C C C 1 —
(2) 1G 5A C C C 0.88 (0.28–2.75) 0.82
(3) 2G 5A C C C 0.36 (0.09–1.48) 0.16
(4) 1G 6A C C C 0.99 (0.28–3.44) 0.98
(5) 2G 6A C C T 0.37 (0.08–1.77) 0.21
(6) 1G 6A C C T 2.59 (0.61–11.09) 0.2
(7) 1G 5A C T C 2.34 (0.59–9.29) 0.23
(8) 1G 5A C C T 5.93 (1.06–33.19) <0.05
(9) 2G 5A T C C 0.98 (0.16–5.93) 0.98
OR: odds ratio; CI: confidence interval; result is statistically significant for p value < 0.05.
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by hypertension and proteinuria [20]. High MMP9 activity
has also been observed in the umbilical cord plasma of
preeclamptic newborns [21]. A similar observation of the
elevated level of MMP9 has also been reported in the
serum of preeclamptic women [22].
The studies conducted by Poon et al. [22], Galewska et al.
[21], and Lockwood et al. [20] may suggest that the carriage
of the TT genotype of −1562C/T polymorphism by expecting
women could be related to the development of preeclampsia.
However, study of Coolman et al. [23] on population of
Dutch women whose gestation proceeded with or without
preeclampsia pointed that the carriers of T allele had a lower
risk of development of hypertension and proteinuria during
pregnancy [23]. Our present study points at the lack of signif-
icant discrepancy in the distribution of the TT genotype and
T allele between the study and control groups. The discrep-
ancy between our study and the study of Coolman et al.
[23] may be related to the population differences between
Polish and Dutch preeclamptic women or various criteria
of qualification of women on both studies. Results of our
study are in agreement with those of Palei et al. [24], who
noted that the carriage of the T allele at −1562C/T MMP9
is not related with the development of preeclampsia.
The most comprehensively described metalloproteinase
other than MMP9 is MMP2, which has been strongly impli-
cated in the process of trophoblast invasion. The present
study examines two functional SNPs (−735 C/T and −1306
C/T) localized in the promoter region of the MMP2 gene
which are related to the regulation ofMMP2 gene expression.
The occurrence of thymidine at the −735 and −1306 posi-
tions negates the binding site for transcription factor Sp-1,
thus decreasing the promoter activity of MMP2 [25, 26].
An elevated MMP2 level was observed in the blood of
preeclamptic women [27]. In addition, Palei et al. [28] found
−1306C/T and −735C/T MMP2 SNPs to be associated with
elevatedMMP2 levels in the plasma of preeclamptic Brazilian
women and mothers whose pregnancies were accompanied
by hypertension; however, they did not find any significant
differences in the genotype or allele frequency distributions
for the two SNPs when hypertensive or preeclamptic patients
were compared with healthy cases [28]. These observations,
in respect to −1306C/T polymorphism, were confirmed by
Leonardo et al. among a Brazilian population [29]. Results
of our study in respect to −1306C/T and −735C/T MMP2
gene polymorphisms did not identify any significant rela-
tionship for genotype nor for allele distribution between
preeclamptic and noncomplicated mothers or between their
children; thus, they are in agreement with the results of Palei
et al. [28] and Leonardo et al. [29].
Our univariate analyses found that homozygous 1G/1G
of MMP1 is more frequent in both mother and child in
the preeclamptic group. The 1G/1G genotype is related
to a lower tendency for MMP1 gene expression [30]. Some
studies note that the reduction of MMP1 levels in the umbil-
ical cord blood, placenta, and decidua is characteristic for
patients whose gestation is accompanied by preeclampsia
[31, 32]. Interestingly, our univariate analysis comparing
the male and female children of the study and control groups
found almost a five times greater likelihood of preeclampsia
in the mother of female fetuses whose MMP1 genotype is
1G/1G (OR=4.58, 95% CI 1.43–14.67; p < 0 02): these
female children may have a higher tendency to develop pre-
eclampsia if they later become pregnant. Moreover, simulta-
neous carriage of 1G/1G polymorphisms by mother and fetus
appears to more than double the risk of occurrence of pre-
eclampsia (OR=2.39, 95% CI 1.01–5.65). Our findings do
not confirm those of Jurajda et al. [33], who did not find
any significant association between 1G/2G MMP1 gene
polymorphisms and pregnancy hypertension in a Cauca-
sian population; however, the study of Jurajda et al. included
women with recognized preeclampsia, eclampsia, and
chronic hypertension, while patients with chronic hyperten-
sion were excluded in the present study.
Our findings also associate carriage ofMMP3 5A/6A with
the appearance of preeclampsia. The carriage of the 5A/5A
genotype by the mother or the 5A/6A genotype by her child
appears to increase the likelihood of the development of
preeclampsia by over two times: OR=2.76 for 5A/5A (95%
CI 1.17–6.49; p < 0 05) and OR=2.44 for 5A/6A (95% CI
1.16–5.13; p < 0 05). When both mother and fetus are
carriers of both 5A/5A and 5A/6A MMP3 polymorphisms,
respectively, the risk of occurrence of preeclampsia is dou-
bled OR=4.57 (95% CI 1.85–11.26). Our observations may
explain the results of other studies, which note that the
MMP3 level is significantly higher in the decidual cells of
preeclamptic mothers than gestational age-matched controls
[5, 20]. The 5A variant is associated with greater promoter
activity than variant 6A. Interestingly, the majority of chil-
dren born from mothers who developed preeclampsia were
heterozygous 5A/6A: a genotype associated with moderate
MMP3 level. This may explain various observations accord-
ing to MMP3 levels and preeclampsia presented in numerous
studies. GDS3467 and GDS2080 studies included in the GEO
Profile database demonstrate a lack of association between
placental MMP3 gene expression levels and preeclampsia,
whereas others show downregulation of MMP3 levels in pre-
eclamptic fetal origin cells and in preeclamptic extravillous
trophoblast cells [12, 34].
One potential limitation of this study may be its relatively
small number size: 86 mothers and 86 children in the
study group and 85 mothers and 85 children in the con-
trols. The power analyses (estimated using the G∗Power
tool [35, 36]; data not included in Results) for the chi2
tests which yielded significant results indicated quite high
power (between 80 and 98%): the chi2 tests for maternal
1G/1G MMP1 and 1G/2G MMP1 gene polymorphisms
were 82% and 95%, respectively; the chi2 test for maternal
5A/5A MMP3 was 93%; the chi2 tests for fetal 1G/1G and
2G/2G were 89% and 98%, respectively. Conversely, the
power analyses for chi2 tests which did not yield signifi-
cant results presented relatively low power (below 80%)
and for this reason, the results could be inconclusive. This
low power may be attributed to the relatively small number
of cases qualified to the study and/or the rare appearance of
minor variants for −735 C/T MMP2 (rs2285053), −1306
C/T MMP2 (rs243865), and −1562C/T MMP9 (rs3918242)




To summarize, our findings suggest that maternal SNPs
−1607 1G/1G MMP1 and −1171 5A/5A MMP3 are inde-
pendency important genetic factors associated with the
occurrence of preeclampsia in Polish population. The
simultaneous carriage of 1G/1G MMP1 and 5A/5A MMP3
polymorphisms by mother increases over 10-fold her risk
to preeclampsia development. The fetal set of 1G/1G
MMP1- and 5A/6A MMP3-studied polymorphisms also
contributes to maternal predisposition of occurrence of
preeclampsia OR=6.54 (95% CI 2.13–20.01, p < 0 01).
Additionally, simultaneous maternal and fetal 1G/1G
homozygosity increases the risk of preeclampsia develop-
ment 2.39-fold, whereas the set of maternal 5A/5A and fetal
5A/6A MMP3 genotypes elevated the risk of occurrence of
the studied disease by over 4.5 times. Moreover, our study
confirms the observations of other researchers that the pro-
moter polymorphisms of the MMP2 and MMP9 genes exert
an insignificant effect on preeclampsia development.
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